.png){kind=small}
WHAT IT IS
A synthetic analogue of growth hormone–releasing hormone (GHRH) that signals the pituitary gland to release growth hormone.
PHYSICIAN-DIRECTED SERMORELIN CARE IN FLORIDA
Sermorelin: Dosage, FDA Status, and What the Evidence Actually Supports
There is no FDA-approved adult dose of sermorelin. Approval was withdrawn in 2009, and what is prescribed today is compounded. Here is what the label actually covered, what compounding pharmacies prepare, and what the evidence does and does not establish.
Timothy Mackey, D.O., Medical Director
Florida License OS9185 · Updated September 2026
A consultation does not guarantee a prescription. Eligible Florida patients may be seen by telemedicine when clinically appropriate.
Timothy Mackey, D.O.Medical Director · Physician-led evaluation and monitoring
PHYSICIANIndividual evaluation
FLORIDALicense OS9185
★★★★★4.9 Google rating
A+BBB rating
MONITORINGOngoing follow-up
Three things to know before deciding
REGULATORY STATUS
FDA approval was withdrawn in June 2009 — for business reasons, not safety or effectiveness. There is no marketed FDA-approved sermorelin product in the United States today.
CLINICAL LENS
It is not a shortcut for anti-aging, muscle gain, or weight loss. History, symptoms, IGF-1, glucose and risk factors all matter before anything is prescribed.
CLINICAL CONTEXT
What is sermorelin, and is it growth hormone?
Sermorelin acts through the body’s growth-hormone signaling pathway rather than supplying growth hormone directly. Its effect depends on pituitary function and can increase insulin-like growth factor-1 (IGF-1).
That mechanism is clinically relevant, but it does not prove broad claims commonly made online about fat loss, recovery, sleep, or “reversing aging.” A responsible decision begins with an individualized medical evaluation.
Read the peptide therapy cornerstone guide →What is the sermorelin dosage?
There is no FDA-approved adult sermorelin dose. That is the accurate answer, and it is not the answer most pages give.
What does exist is a convention among compounding pharmacies, and those pharmacies publish it openly. Empower Pharmacy states that a common adult dosing regimen for growth hormone deficiency is 0.2 to 0.3 mg of sermorelin acetate injected subcutaneously once daily at bedtime. Olympia Pharmaceuticals and other compounders describe similar nightly subcutaneous dosing in the 200 to 300 microgram range.
Read that for what it is. It describes what compounders prepare and what prescribers commonly order. It is not an approved dosing standard, it was not established in registration trials for adult use, and it varies between pharmacies.
The only dose the FDA ever approved was weight-based, for children with growth failure, in a product discontinued in 2009. It does not translate to an adult.
What actually determines dosing
Baseline IGF-1, the clinical picture, response on follow-up labs, and prescriber judgment. A number taken off a website and self-administered is not a treatment plan, and the pharmacy selling the vial is not the party monitoring your IGF-1.
Who may be a candidate, and who should not use sermorelin
An evaluation may include
- Symptoms, goals, sleep, recovery, and medical history
- Medication and supplement review
- IGF-1 and other laboratories when clinically appropriate
- Discussion of realistic expectations and alternatives
Important reasons for added caution
- Active or recent malignancy
- Pituitary disease or unexplained endocrine findings
- Pregnancy or breastfeeding
- Uncontrolled glucose abnormalities or significant untreated illness
A four-step physician-guided process
Consultation
Review symptoms, goals, medical history, medications, and prior treatment.
Evaluation
Complete a focused exam, records review, and labs when clinically appropriate.
Shared decision
Compare evidence, regulatory status, alternatives, uncertainty, cost, and risk.
Follow-up
If treatment is appropriate, monitor response, side effects, and ongoing need.
SAFETY & MONITORING
What responsible care should address
Sermorelin can affect a hormone pathway with effects throughout the body. Monitoring is more than a formality.
- Injection-site reactions, headache, flushing, dizziness, or nausea may occur.
- Fluid retention, joint discomfort, changes in glucose handling, or an excessive IGF-1 response require reassessment.
- Compounded products are not reviewed by FDA for safety, effectiveness, or manufacturing quality in the same way as an approved finished drug.
- Competitive athletes should verify current anti-doping rules before considering any growth-hormone–related substance.
Call 911 for a medical emergency. Contact the prescribing clinician promptly for concerning or persistent symptoms.
What are the side effects of sermorelin?
From the GEREF prescribing information, the most common treatment-related adverse event was a local injection-site reaction: pain, swelling, or redness. Rotating injection sites was part of the labeled administration guidance. That is the effect you are most likely to actually encounter, and it is manageable.
One finding deserves more attention than it gets. The GEREF prescribing information reported that a large proportion of patients developed anti-GRF antibodies at some point during treatment. In the pediatric population studied, this did not appear to affect growth or produce a distinct adverse-reaction pattern. It is a documented immunological response to the drug, and it is rarely mentioned in consumer material about sermorelin.
Because sermorelin raises growth hormone and therefore IGF-1, the considerations that apply to any growth-hormone-raising therapy apply here, which is why IGF-1 and glucose belong in monitoring rather than being optional.
Do sermorelin pills, tablets, or nasal sprays work?
Sermorelin is a peptide, a short chain of amino acids. Peptides taken by mouth are broken down by digestive enzymes, which is why peptide medicines are generally injected rather than swallowed. The FDA-approved sermorelin product was an injection.
Nasal formulations attempt to bypass digestion, but absorption and dose consistency by that route have not been established for this drug to an approval standard.
If you are considering an oral or spray product, the question worth asking the seller is what evidence exists that it delivers the peptide intact.
Sermorelin vs. tesamorelin and ipamorelin
Sermorelin vs. tesamorelin
Both are GHRH analogs and both raise the body's own growth hormone. The difference that matters is regulatory. Tesamorelin (Egrifta) holds a current FDA approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, with an approved adult dose of 1.28 mg once daily for EGRIFTA WR. Sermorelin's approval was withdrawn in 2009, its only approved indication was pediatric, and it has never had an approved adult dose.
Tesamorelin has a current adult approval, a label, and studied dosing. Sermorelin does not. If the two are being presented as interchangeable peptides, that is the difference being glossed over.
Sermorelin vs. ipamorelin
Different receptors. Sermorelin is a GHRH analog acting on the GHRH receptor. Ipamorelin is a growth-hormone secretagogue acting on the ghrelin receptor. Neither holds a current FDA approval for adult use, and both are compounded when prescribed. Claims that one is definitively superior for adult outcomes outrun the published evidence for both.
The full side-by-side comparison, including dosing, safety, and whether they can be combined, is on its own page: tesamorelin vs. sermorelin.
Is sermorelin a weight-loss treatment?
Sermorelin has no FDA-approved weight-loss indication. Its approved indication was pediatric growth failure, not body composition in adults.
Semaglutide and tirzepatide do hold FDA-approved indications for weight management. That is a difference in regulatory status, not a judgment about any individual patient, but if weight loss is the goal it is the difference worth understanding before spending money.
If that is what brought you here, the more relevant starting points are our medically supervised weight loss programs, semaglutide, and tirzepatide.
Put this option in the right clinical context
Tesamorelin
FDA-approved for one specific indication
Explore this page →Peptide therapy guide
Compare approved, compounded, and investigational categories
Explore this page →In-person and telemedicine care
NovaGenix serves patients at 609 N. Hepburn Ave., Suite 106, Jupiter, Florida, with telemedicine available to eligible patients throughout Florida.
Clear next steps after evaluation
Cost and availability depend on the medically appropriate option, pharmacy or product, monitoring, and insurance status. The team explains expected costs before treatment begins.
Common questions about sermorelin
Is sermorelin FDA-approved?
Current sermorelin preparations used in practice are not FDA-approved finished drug products. If compounded, the preparation is made for an individual patient by a licensed pharmacy and is not equivalent to FDA approval.
Is sermorelin the same as growth hormone?
No. Sermorelin is a GHRH analogue that signals the pituitary gland; injectable growth hormone supplies growth hormone directly.
Will sermorelin cause weight loss or build muscle?
Those outcomes should not be promised. Any change varies by patient, and broad anti-aging, fat-loss, or muscle-building claims are not established indications.
What testing is considered?
The physician may review IGF-1, glucose-related markers, thyroid or other endocrine data, and additional labs based on history and symptoms.
Can Florida patients be seen by telehealth?
Eligible Florida patients may begin with telemedicine when clinically appropriate. Some evaluations or follow-up needs may require in-person care or local laboratory testing.
Start with a physician conversation
Discuss your goals, medical history, evidence-based options, and whether this therapy—or a different approach—may be appropriate.
